Home/Filings/4/0001618835-20-000019
4//SEC Filing

Culwell Kelly 4

Accession 0001618835-20-000019

CIK 0001618835other

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 4:32 PM ET

Size

9.5 KB

Accession

0001618835-20-000019

Insider Transaction Report

Form 4
Period: 2020-02-05
Culwell Kelly
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2020-02-05$5.21/sh+3,688$19,21447,226 total
  • Award

    Common Stock

    2020-02-05+150,000197,226 total
  • Award

    Stock option (right to buy)

    2020-02-05+100,000100,000 total
    Exercise: $4.87Exp: 2030-02-05Common Stock (100,000 underlying)
Footnotes (5)
  • [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Evofem Biosciences, Inc. 2019 Employee Stock Purchase Plan (2019 ESPP), for the ESPP purchase period of June 17, 2019 through December 13,2019. This transaction is also exempt under Rule 16b-3(c).
  • [F2]The reporting person is voluntarily reporting this transaction as of February 5, 2020, but the actual transaction took place on December 13, 2020, the last trading day of the purchase period under the 2019 ESPP.
  • [F3]In accordance with the 2019 ESPP, these shares were purchased based on 85% of the closing stock price on December 13, 2019, the last trading day of the purchase period.
  • [F4]The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2020.
  • [F5]The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 5, 2020

Issuer

Evofem Biosciences, Inc.

CIK 0001618835

Entity typeother

Related Parties

1
  • filerCIK 0001726183

Filing Metadata

Form type
4
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:32 PM ET
Size
9.5 KB